Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$4.33
+2.4%		$4.80
$3.50
▼
$5.45
$837.99M0.768.00 million shs2.11 million shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$18.85
+5.1%		$26.82
$11.36
▼
$35.83
$884.58M1.342.15 million shs817,835 shs
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$10.23
+6.0%		$12.66
$6.39
▼
$26.95
$811.77M1.441.11 million shs1.07 million shs
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$4.99
+3.5%		$6.50
$4.11
▼
$16.45
$187.68M-0.24366,303 shs403,064 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
+0.24%+1.93%-15.57%-6.42%-4.08%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
+7.68%+8.99%-37.92%-36.52%-8.05%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
+1.37%-3.98%-23.17%-33.31%+37.07%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
+10.30%-12.36%-28.59%-25.39%-17.89%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$4.33
+2.4%		$4.80
$3.50
▼
$5.45
$837.99M0.768.00 million shs2.11 million shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$18.85
+5.1%		$26.82
$11.36
▼
$35.83
$884.58M1.342.15 million shs817,835 shs
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$10.23
+6.0%		$12.66
$6.39
▼
$26.95
$811.77M1.441.11 million shs1.07 million shs
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$4.99
+3.5%		$6.50
$4.11
▼
$16.45
$187.68M-0.24366,303 shs403,064 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
+0.24%+1.93%-15.57%-6.42%-4.08%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
+7.68%+8.99%-37.92%-36.52%-8.05%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
+1.37%-3.98%-23.17%-33.31%+37.07%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
+10.30%-12.36%-28.59%-25.39%-17.89%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
2.50
Moderate Buy$5.0015.47% Upside
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
2.73
Moderate Buy$25.6736.16% Upside
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
2.88
Moderate Buy$33.33225.84% Upside
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
2.43
Hold$17.75255.71% Upside

Current Analyst Ratings Breakdown

Latest TRDA, CRVS, ABUS, and AVBP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/20/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$45.00 ➝ $29.00
10/19/2026
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingNeutral
10/19/2026
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingNeutral
10/16/2026
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
10/16/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$29.00
10/15/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/8/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$47.00 ➝ $27.00
10/7/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$45.00 ➝ $18.00
10/7/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$42.00 ➝ $29.00
10/7/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$40.00 ➝ $20.00
10/7/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
JonesTrading logo
JonesTrading
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$45.00 ➝ $22.00
(Data available from 10/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$14.08M60.92N/AN/A$0.40 per share10.83
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/A$7.44 per shareN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/A$0.13 per share76.13$0.73 per shareN/A
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$25.42M7.64N/AN/A$8.01 per share0.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$33.50M$0.795.35N/AN/A84.22%90.98%82.34%11/16/2026 (Estimated)
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$166.31M-$3.62N/AN/AN/AN/A-50.26%-46.66%11/16/2026 (Estimated)
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$15.28M-$0.61N/AN/AN/AN/A-36.15%-33.62%11/3/2026 (Estimated)
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$143.75M-$3.96N/AN/AN/A-3,537.73%-57.61%-46.54%11/5/2026 (Estimated)

Latest TRDA, CRVS, ABUS, and AVBP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q3 2026
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$0.0232N/AN/AN/A$1.00 millionN/A
11/16/2026Q3 2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$1.06N/AN/AN/A$0.80 millionN/A
11/5/2026Q3 2026
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$0.98N/AN/AN/A$2.13 millionN/A
11/3/2026Q3 2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.1921N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$0.02-$0.03-$0.01-$0.03$0.70 million$1.01 million
8/12/2026Q2 2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.9873-$1.05-$0.0627-$1.05N/AN/A
8/6/2026Q2 2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.1591-$0.19-$0.0309-$0.19N/AN/A
8/5/2026Q2 2026
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$0.9738-$1.01-$0.0363-$1.01$2.32 million$0.90 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
N/AN/AN/AN/AN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
N/A
81.42
81.42
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/A
14.16
14.16
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
16.16
16.16
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/A
10.89
10.89

Institutional Ownership

CompanyInstitutional Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
43.79%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
9.48%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
86.39%

Insider Ownership

CompanyInsider Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
19.90%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
8.58%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
19.70%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
9.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
19198.11 million158.68 millionOptionable
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
7749.31 million45.08 millionOptionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3784.12 million67.55 millionOptionable
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
15238.94 million35.24 millionOptionable

Recent News About These Companies

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Has Average Price Target of $17.75
October 18 at 4:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-entrada-therapeutics-inc-nasdaq-trda-stock-has-average-price-target-of-1775-2026-10-18/
Entrada Therapeutics Advances Duchenne Study To Highest Planned Dose Level
October 14, 2026  |  rttnews.comhttps://www.rttnews.com/3698959/entrada-therapeutics-advances-duchenne-study-to-highest-planned-dose-level.aspx
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
October 14, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/independent-safety-data-monitoring-committee-recommends-initiation-of-cohort-3-at-the-top-dose-of-18-mg-kg-in-entrada-therapeutics-elevate-44-201-study-1036624958
Entrada Therapeutics clears DMC review, advances DMD study to top dose
October 14, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Entrada+Therapeutics+clears+DMC+review%2C+advances+DMD+study+to+top+dose/27183550.html
Entrada Therapeutics Shares Drop 15% After Phase 1/2 Trial Results
October 14, 2026  |  kucoin.comK
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
October 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3380583/0/en/entrada-therapeutics-announces-positive-results-from-the-first-cohort-of-participants-with-duchenne-muscular-dystrophy-dmd-in-the-phase-1-2-elevate-45-201-study-of-entr-601-45.html
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study
October 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3380577/0/en/independent-safety-data-monitoring-committee-recommends-initiation-of-cohort-3-at-the-top-dose-of-18-mg-kg-in-entrada-therapeutics-elevate-44-201-study.html
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity
October 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4953206-entrada-therapeutics-weak-dystrophin-data-may-be-creating-a-buying-opportunity
Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Lowered by Wall Street Zen
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-entrada-therapeutics-nasdaq-trda-stock-rating-lowered-by-wall-street-zen-2026-09-26/
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Rating of "Moderate Buy" from Analysts
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-entrada-therapeutics-inc-nasdaq-trda-receives-average-rating-of-moderate-buy-from-analysts-2026-09-23/
Entrada Therapeutics, Inc.: Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
September 10, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69544786-entrada-therapeutics-inc-entrada-therapeutics-announces-recipients-of-fourth-annual-dreams-grant-program-399.htm
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359342/0/en/entrada-therapeutics-announces-recipients-of-fourth-annual-dreams-grant-program.html
Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 28,837 Shares of Stock
September 10, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-trda-insider-buying-and-selling-2026-09-10/
Analysts Conflicted on These Healthcare Names: Definitive Healthcare Corp (DH) and Entrada Therapeutics Inc (TRDA)
September 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/DH/pressreleases/4442226/analysts-conflicted-on-these-healthcare-names-definitive-healthcare-corp-dh-and-entrada-therapeutics-inc-trda/
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $180,691.89 in Stock
September 4, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-trda-insider-buying-and-selling-2026-09-04/
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355530/0/en/entrada-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock
September 1, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-trda-insider-buying-and-selling-2026-09-01/
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $102,857.14 in Stock
August 27, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-trda-insider-buying-and-selling-2026-08-27/
Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares of Stock
August 11, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-trda-insider-buying-and-selling-2026-08-11/
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
August 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/entrada-therapeutics-reports-second-quarter-110000613.html
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
August 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2968399/entrada-therapeutics-inc-trda-reports-q2-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2968399

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arbutus Biopharma stock logo

Arbutus Biopharma NASDAQ:ABUS

$4.33 +0.10 (+2.36%)
Closing price 04:00 PM Eastern
Extended Trading
$4.28 -0.05 (-1.15%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

ArriVent BioPharma stock logo

ArriVent BioPharma NASDAQ:AVBP

$18.85 +0.91 (+5.07%)
Closing price 04:00 PM Eastern
Extended Trading
$18.88 +0.02 (+0.13%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$10.23 +0.58 (+6.01%)
Closing price 04:00 PM Eastern
Extended Trading
$10.22 -0.02 (-0.15%)
As of 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Entrada Therapeutics stock logo

Entrada Therapeutics NASDAQ:TRDA

$4.99 +0.17 (+3.53%)
Closing price 04:00 PM Eastern
Extended Trading
$4.99 0.00 (-0.10%)
As of 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas